Description
Mechanism of Action
Piroxicam is a NSAID, belonging to the oxicam group. It inhibits prostaglandin synthesis, reduces fever by acting on the heat-regulating center of the hypothalamus, inhibits platelet-aggregating substance thromboxane A2 and reduces pain receptor sensitivity. It also exerts anti-inflammatory effect by lysosomal stabilisation, kinin and leukotriene production, alteration of chemotactic factors and neutrophil activation inhibition.
Absorption: Well absorbed from the GIT (oral); peak plasma concentrations 3-5 hr after an oral dose.
Distribution: Detected in breast milk. Protein-binding: 99%
Metabolism: Hepatic via hydroxylation and conjugation; undergoes enterohepatic recycling.
Excretion: Mainly in urine (as metabolites and unchanged drug), faeces; elimination half-life: 50 hr.
MIMS Class
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
ATC Classification
M01AC01 – piroxicam; Belongs to the class of non-steroidal antiinflammatory and antirheumatic products, oxicams.;
S01BC06 – piroxicam; Belongs to the class of non-steroidal antiinflammatory agents. Used in the treatment of inflammation of the eye.;
M02AA07 – piroxicam; Belongs to the class of non-steroidal antiinflammatory preparations for topical use. Used in the treatment of joint and muscular pains.;
